Stifel analyst Annabel Samimy raised the firm’s price target on MBX Biosciences (MBX) to $50 from $45 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst’s Biopharma coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- Midday Fly By: Meta to slash metaverse spending, Salesforce posts Q3 beat
- Morning Movers: Genesco, Build-A-Bear slide following quarterly results
- MBX Biosciences drops 4% in premarket trading after Goldman initiates with Sell
- MBX Biosciences initiated with a Sell at Goldman Sachs
- MBX Biosciences, Inc.: Strong Financial Outlook and Strategic Direction Support Buy Rating